Emmaus Life Sciences, Inc.

EMMA

OTC

Healthcare

Biotechnology

Torrance, CA, US34 employeesemmausmedical.com

—

At a Glance

AI-generated

FY2025 delivered Emmaus’ first operating profit in recent years, but generic Endari® competition pressured revenue and widened net loss, with the NIT license as a core near-term catalyst.

Revenue breakdown: Endari US (77.4%), Endari International (20.1%), Product And Service Other (2.5%).

8-K

Emmaus Life Sciences reported 2025 annual results with net revenues of $12.5 million, down 25% from 2024, but achieved operating income of $0.2 million due to 34% lower operating expenses, alongside a net loss of $7.2 million.

—

Market Cap

—

Revenue

—

Net Income

Employees34

Fundamentals

How The Business Makes Money

Revenue by Segment

Endari US77.4%($23M)

Endari International20.1%($6M)

Product And Service Other2.5%($731.0K)

Activity

What Changed Recently

Financial Results

Mar 30, 2026

and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t

Material Agreement

Mar 3, 2026

Entry into a Material Definitive Agreement Reference is made to the description of the License and Exclusive Distribution Agreement, or License Agreement, dated

Peer Companies

Company	Price	Change	Market Cap	P/E
BPTHBio-Path Holdings, Inc.	—	—	—	—
VIBEFVibe Growth Corporation	—	—	—	—
PHCGPure Harvest Corporate Gr...	—	—	—	—
NRXCFNRXCF	—	—	—	—
VPROViropro Inc.	—	—	—	—
NPHCNutra Pharma Corp.	—	—	—	—
SQZBSQZ Biotechnologies Compa...	—	—	—	—
YECOYulong Eco-Materials Limi...	—	—	—	—

Analyst View

Company Profile

CIK0000822370

ISINUS29137T1016

CUSIP29137T101

Phone310 214 0065

Address21250 Hawthorne Boulevard, Torrance, CA, 90503, US

SEC EDGAR